What is New Ray Medicine International Holding Operating Cash Flow per Share?
New Ray Medicine International Holding's operating cash flow per share for the
six
months ended in Dec. 2023 was HK$-0.01.
New Ray Medicine International Holding's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.03.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -12.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for New Ray Medicine International Holding's Operating Cash Flow per Share or its related term are showing as below:
HKSE:06108'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -12.4 Med: 25.85 Max: 42.2
Current: -12.4
During the past 12 years, New Ray Medicine International Holding's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.20% per year. The lowest was -12.40% per year. And the median was 25.85% per year.
HKSE:06108's 3-Year OCF Growth Rate is ranked worse than 76.88% of 493
companies
in the Healthcare Providers & Services industry
Industry Median: 9.5
vs HKSE:06108: -12.40
New Ray Medicine International Holding Operating Cash Flow per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
New Ray Medicine International Holding Operating Cash Flow per Share Chart
New Ray Medicine International Holding Annual Data
Competitive Comparison of New Ray Medicine International Holding's Operating Cash Flow per Share
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding's Price-to-Operating-Cash-Flow Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Price-to-Operating-Cash-Flow falls into.
New Ray Medicine International Holding Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of New Ray Medicine International Holding's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
New Ray Medicine International Holding (HKSE:06108) Business Description
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06108 has been successfully added to your 